RESUMO
The authors report a clinical case of an isolated oral histoplasmosis in a hemodialysis patient that presented with fever of unknown origin and had an unremarkable physical examination. During the investigation, a Gallium scan showed uptake in the oral cavity and soon after the oral cavity examination revealed a granulomatous lesion on the tooth 26. Histopathologic findings were compatible with histoplasmosis. The treatment regimen included liposomal amphotericin B followed by itraconazole consolidation therapy, and side effects did not occur. Both clinical evolution and outcome were favorable. Oral histoplasmosis in a non-immunosuppressed patient is extremely rare.
Assuntos
Febre de Causa Desconhecida/etiologia , Febre de Causa Desconhecida/microbiologia , Gengiva/patologia , Histoplasmose/diagnóstico , Histoplasmose/patologia , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Histocitoquímica , Histoplasmose/microbiologia , Humanos , Itraconazol/uso terapêutico , Masculino , Portugal , Diálise RenalRESUMO
Protozoal infections that are efficiently transmitted by blood transfusion include Malaria, Chagas Disease, African Trypanosomiasis, Leshmaniasis, Toxoplasmosis and Babesiosis. With exception of Toxoplasmosis and Leishmaniasis, these diseases are endemic in mainly tropical low income countries and, in non-endemic countries like Portugal, the reported cases are imported from these endemic areas by travelers or immigrants. Globalization, with increasing travel and immigration poses the risk of exposition to these infectious agents and raises the issue of possible transmission by blood transfusion. According to recommendations of the Council of Europe, strategies to prevent the transmission of these infections by blood transfusion have been implemented. Given that the risk is introduced by a specific group of donors, travelers or immigrants from endemic areas, the main strategy to prevent this transmission depends on the identification of these groups of donors using questionnaires during the pre-donation procedures. Additional measures, like serological testing and pathogen inactivation procedures, when available, contribute not only to reduce the risk of transmission but also to avoid unnecessary rejections.